Acumen Pharmaceuticals (ABOS) Insider & Congress Trades

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about ABOS filings

Are insiders buying or selling Acumen Pharmaceuticals Inc (ABOS) stock?

Neither. Acumen Pharmaceuticals Inc (ABOS) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ABOS recently?

None. No member of Congress disclosed a ABOS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ABOS smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Smart money on ABOS

Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Nathan B Fountain, sold $14.3K, open market, filed Jun 10
- Derrell Porter, sold $75.2K, scheduled plan sale, filed Jun 17
Lean short · thin2 sales · $89.5K
1 of 2 on scheduled plans. Form 4 filings.
Congress
No recent politician filings found
Funds
No recent fund filings found
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ABOS filings

Are insiders buying or selling Acumen Pharmaceuticals Inc (ABOS) stock?

Neither. Acumen Pharmaceuticals Inc (ABOS) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ABOS recently?

None. No member of Congress disclosed a ABOS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ABOS smart-money data?

Insiders

What insiders are doing

2 trades · 6 mo

Sold$90K

Sells (2)

PD
Porter Derrell
Dir · Cluster · Jun 17
$75K
sold
FN
Fountain Nathan B
Dir · Cluster · Jun 10
$14K
sold

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 26, 2026

Earnings came in 11.3% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 26, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.35+11.29% beat

-$0.39 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 26, 2026	-$0.35est. -$0.39	+11.29%beat	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 12, 2026	-$0.45est. -$0.41	-11.02%miss	$0.00Yahoo Finance	No year-ago quarter
Mar 31, 2026Reported May 12, 2026	-$0.33est. -$0.46	+28.26%beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Mar 26, 2026	-$0.41est. -$0.56	+26.29%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 12, 2025	-$0.44est. -$0.68	+35.29%beat	Not on file	Not on file
Jun 30, 2025Reported Aug 12, 2025	-$0.68est. -$0.52	-30.77%miss	Not on file	Not on file
Mar 31, 2025Reported May 13, 2025	-$0.48est. -$0.55	+12.73%beat	Not on file	Not on file
Dec 31, 2024Reported Mar 27, 2025	-$0.62est. -$0.37	-69.49%miss	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $0.23
High: $0.24
Low: $0.23
Prev close: $0.23
52-wk high: $3.60
52-wk low: $0.19
Mkt cap: $16.6M
ROE: -162.7%
Beta: 0.45
P/S: 538.8x
P/B: 0.5x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $17M

Valuation

P/S538.78
P/B0.48

Quality

Operating margin0.0%
ROE-162.7%
ROA-57.5%

Growth

Beta0.45

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

17oversold

20D volatility

860%annualized

52-week range

$0.23

$0.19$3.60

20D support

$0.19recent floor

20D resistance

$2.52recent ceiling

Returns

5D +6.3%20D -86.8%60D -91.6%

Price vs moving averages

SMA20 -81.2%SMA50 -88.3%SMA200 -90.5%

Volume pace

10.79xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Oct 26, 2026

-$0.35est. -$0.39

+11.29%

$0.00Yahoo Finance

No year-ago quarter

Jun 30, 2026Aug 12, 2026

-$0.45est. -$0.41

-11.02%

$0.00Yahoo Finance

No year-ago quarter

Mar 31, 2026May 12, 2026

-$0.33est. -$0.46

+28.26%

$0.00Yahoo Finance

No year-ago quarter

Dec 31, 2025Mar 26, 2026

-$0.41est. -$0.56

+26.29%

$0.00Yahoo Finance

No year-ago quarter

Sep 30, 2025Nov 12, 2025

-$0.44est. -$0.68

+35.29%

Not on file

Jun 30, 2025Aug 12, 2025

-$0.68est. -$0.52

-30.77%

Not on file

Mar 31, 2025May 13, 2025

-$0.48est. -$0.55

+12.73%

Not on file

Dec 31, 2024Mar 27, 2025

-$0.62est. -$0.37

-69.49%

Not on file

Acumen Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about ABOS filings

Smart money on ABOS

Questions about ABOS filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 11.3% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Acumen Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about ABOS filings

Smart money on ABOS

Questions about ABOS filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 11.3% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Acumen Pharmaceuticals Inc

Overview

Questions about ABOS filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Acumen Pharmaceuticals Inc

Overview

Questions about ABOS filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.